Yuhan Corporation has in-licensed GI Innovation’s allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion.
Yuhan and GI Innovation’s collaboration to develop next-generation allergy treatment will cover all four major allergic diseases, which are allergic asthma, chronic urticaria, atopic dermatitis, and food allergy.
Under this license and co-development agreement, Yuhan has global rights, excluding Japan, to develop and commercialize GI-301, while GI Innovation will collaborate on the development.
According to GI Innovation, GI-301 can be competitive in the market, since it has 1) higher inhibition of IgE in animal testing compared to Xolair, which is the only existing IgE antibody approved by the FDA, and 2) less risk of anaphylaxis, the most common side effect of anti-IgE drugs.
In September, GI 301 will enter phase 1 clinical trials in Korea.
- Related Article: http://www.koreaherald.com/view.php?ud=20200701000846